{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:06Z","timestamp":1787008626797,"version":"build-2736575974"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI119037"],"award-info":[{"award-number":["R01AI119037"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["220587\/Z\/20\/Z"],"award-info":[{"award-number":["220587\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Quantitative markers of tuberculosis disease burden are essential for assessing treatment response and optimizing therapeutic strategies. This study evaluated the impact of antimicrobial plasma drug levels on time-to-positivity (TTP) trajectories in patients with drug-susceptible tuberculosis and explored the relationship between bacillary clearance and treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with drug susceptible pulmonary tuberculosis initiating treatment were recruited in Worcester, South Africa. Weekly sputum samples were collected for 12 weeks, with bacterial load quantified using Mycobacterial Growth Indicator Tubes, yielding TTP. Nonlinear mixed-effects modeling was used to empirically describe longitudinal TTP, assessing rifampicin exposure and other participant characteristics as covariates. TTP trajectories were stratified by treatment outcomes to identify trends between change in TTP and outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 402 participants were included, of whom 60% were male. Median age was 37 years (interquartile ratio 26\u201348) and 90% had successful treatment outcomes (were cured or completed treatment) at 6 months with 3% who experienced treatment failure, 2% died, 1% transferred, and 4% were lost to follow-up. Baseline smear grade and lung cavitation decreased baseline TTP. Higher rifampicin concentration area under the curve was associated with faster longitudinal change in TTP, whereas lung cavitation and older age were associated with slower longitudinal change. Furthermore, slower change in TTP during the first 12 weeks of treatment was linked to treatment failure at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings highlight the role of rifampicin plasma exposure in optimizing bacillary clearance and improving treatment outcomes, even within standard dosing regimens for drug-susceptible tuberculosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf586","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:57:01Z","timestamp":1761134221000},"page":"e1014-e1022","source":"Crossref","is-referenced-by-count":1,"title":["Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-8210","authenticated-orcid":false,"given":"Marie","family":"Wijk","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-079X","authenticated-orcid":false,"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9002-8087","authenticated-orcid":false,"given":"Kamunkhwala","family":"Gausi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0235-6716","authenticated-orcid":false,"given":"Bronwyn","family":"Myers","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Curtin enAble Institute, Curtin University , Bentley, Western Australia ,","place":["Australia"]},{"name":"Mental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council , Cape Town ,","place":["South Africa"]},{"name":"Department of Psychiatry and Mental Health, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-0565","authenticated-orcid":false,"given":"Tara","family":"Carney","sequence":"additional","affiliation":[{"name":"Mental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council , Cape Town ,","place":["South Africa"]},{"name":"Department of Psychiatry and Mental Health, University of Cape Town , Cape Town ,","place":["South Africa"]},{"name":"Department of Psychology, University of Johannesburg , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0588-8235","authenticated-orcid":false,"given":"Laura F","family":"White","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Center for Health Data Science, Boston University School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danie","family":"Theron","sequence":"additional","affiliation":[{"name":"Department of Medical Services, Brewelskloof Hospital , Worcester ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9787-2785","authenticated-orcid":false,"given":"Charles D H","family":"Parry","sequence":"additional","affiliation":[{"name":"Mental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council , Cape Town ,","place":["South Africa"]},{"name":"Department of Psychiatry and Mental Health, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-7895","authenticated-orcid":false,"given":"C Robert","family":"Horsburgh","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Boston University School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noorjahn","family":"Rawoot","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research\/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-7358","authenticated-orcid":false,"given":"Robin M","family":"Warren","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research\/South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-6506","authenticated-orcid":false,"given":"Richard","family":"Court","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9883-610X","authenticated-orcid":false,"given":"Sanjana G","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3871-5760","authenticated-orcid":false,"given":"Maha R","family":"Farhat","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-7823","authenticated-orcid":false,"given":"Chan\u00e9","family":"Buys","sequence":"additional","affiliation":[{"name":"Desmond Tutu Tuberculosis Centre, Department of Paediatrics and Child Health, Stellenbosch University , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-2348","authenticated-orcid":false,"given":"Samantha","family":"Malatesta","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5828-8500","authenticated-orcid":false,"given":"Sarah E","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Boston University School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchitra","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Boston University Chobanian Avedisian School of Medicine and Boston Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-6226","authenticated-orcid":false,"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4239-3685","authenticated-orcid":false,"given":"Karen R","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Boston University Chobanian Avedisian School of Medicine and Boston Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-4559","authenticated-orcid":false,"given":"Frank","family":"Kloprogge","sequence":"additional","affiliation":[{"name":"Institute for Global Health, University College London , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"2026052019231178800_ciaf586-B1","volume-title":"Global tuberculosis report","author":"WHO","year":"2024"},{"key":"2026052019231178800_ciaf586-B2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(09)70042-8","article-title":"Biomarkers for tuberculosis disease activity, cure, and relapse","volume":"9","author":"Wallis","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2026052019231178800_ciaf586-B3","doi-asserted-by":"crossref","first-page":"ofaa218","DOI":"10.1093\/ofid\/ofaa218","article-title":"Longitudinal pharmacokinetic-pharmacodynamic biomarkers correlate with treatment outcome in drug-sensitive pulmonary tuberculosis: a population pharmacokinetic-pharmacodynamic analysis","volume":"7","author":"Kloprogge","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026052019231178800_ciaf586-B4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1586\/17476348.2016.1166960","article-title":"Assessment of treatment response in tuberculosis","volume":"10","author":"Rockwood","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"2026052019231178800_ciaf586-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/civ195","article-title":"Pharmacodynamic modeling of bacillary elimination rates and detection of bacterial lipid bodies in sputum to predict and understand outcomes in treatment of pulmonary tuberculosis","volume":"61","author":"Sloan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026052019231178800_ciaf586-B6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.01876-12","article-title":"A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture","volume":"57","author":"Chigutsa","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052019231178800_ciaf586-B7","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1164\/rccm.202103-0534OC","article-title":"A semimechanistic model of the bactericidal activity of high-dose isoniazid against multidrug-resistant tuberculosis: results from a randomized clinical trial","volume":"204","author":"Gausi","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026052019231178800_ciaf586-B8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/infdis\/jiy242","article-title":"Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations","volume":"218","author":"Svensson","year":"2018","journal-title":"J Infect Dis"},{"key":"2026052019231178800_ciaf586-B9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and safety of high-dose rifampin in pulmonary tuberculosis a randomized controlled trial","volume":"198","author":"Vel\u00e1squez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026052019231178800_ciaf586-B10","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/cid\/ciac228","article-title":"High intrapulmonary rifampicin and isoniazid concentrations are associated with rapid sputum bacillary clearance in patients with pulmonary tuberculosis","volume":"75","author":"McCallum","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026052019231178800_ciaf586-B11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.03931-14","article-title":"Impact of nonlinear interactions of pharmacokinetics and mics on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis","volume":"59","author":"Chigutsa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052019231178800_ciaf586-B12","doi-asserted-by":"crossref","first-page":"e0019024","DOI":"10.1128\/aac.00190-24","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid","volume":"68","author":"Simeon","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052019231178800_ciaf586-B13","doi-asserted-by":"crossref","first-page":"e0179420","DOI":"10.1128\/AAC.01794-20","article-title":"Longitudinal model-based biomarker analysis of exposure-response relationships in adults with pulmonary tuberculosis","volume":"65","author":"Gewitz","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052019231178800_ciaf586-B14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/s12879-021-06133-4","article-title":"Comparing rates of mycobacterial clearance in sputum smear-negative and smear-positive adults living with HIV","volume":"21","author":"Machowski","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026052019231178800_ciaf586-B15","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1093\/cid\/ciac445","article-title":"Tuberculosis molecular bacterial load assay reveals early delayed bacterial killing in patients with relapse","volume":"76","author":"Ntinginya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026052019231178800_ciaf586-B16","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s12879-018-3396-y","article-title":"Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol","volume":"18","author":"Myers","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2026052019231178800_ciaf586-B17","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment","author":"WHO","year":"2020"},{"key":"2026052019231178800_ciaf586-B18","author":"WHO","year":"1999"},{"key":"2026052019231178800_ciaf586-B19","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/jac\/dkae206","article-title":"The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs","volume":"79","author":"Wijk","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026052019231178800_ciaf586-B20","doi-asserted-by":"publisher","author":"Ghanem","DOI":"10.1101\/2024.08.19.24311411"},{"key":"2026052019231178800_ciaf586-B21","doi-asserted-by":"publisher","author":"Kulkarni","DOI":"10.1101\/2025.08.05.25333066"},{"key":"2026052019231178800_ciaf586-B22","doi-asserted-by":"crossref","first-page":"e1012260","DOI":"10.1371\/journal.pcbi.1012260","article-title":"Quantitative drug susceptibility testing for Mycobacterium tuberculosis using unassembled sequencing data and machine learning","volume":"20","author":"Lachapelle","year":"2024","journal-title":"PLoS Comput Biol"},{"key":"2026052019231178800_ciaf586-B23"},{"key":"2026052019231178800_ciaf586-B24","volume-title":"NONMEM user's guide, part V. Introductory guide","author":"Boeckmann","year":"2011"},{"key":"2026052019231178800_ciaf586-B25","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat Med"},{"key":"2026052019231178800_ciaf586-B26","doi-asserted-by":"crossref","first-page":"9400","DOI":"10.1038\/s41467-024-53273-7","article-title":"Risk-stratified treatment for drug-susceptible pulmonary tuberculosis","volume":"15","author":"Chang","year":"2024","journal-title":"Nat Commun"},{"key":"2026052019231178800_ciaf586-B27","doi-asserted-by":"crossref","first-page":"e01054-17","DOI":"10.1128\/AAC.01054-17","article-title":"Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis","volume":"61","author":"Aarnoutse","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052019231178800_ciaf586-B28","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026052019231178800_ciaf586-B29","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052019231178800_ciaf586-B30","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052019231178800_ciaf586-B31","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/cid\/ciad051","article-title":"Analysis of dynamic efficacy endpoints of the Nix-TB Trial","volume":"76","author":"Solans","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026052019231178800_ciaf586-B32","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1513\/AnnalsATS.201312-447OC","article-title":"Does alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India","volume":"11","author":"Duraisamy","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2026052019231178800_ciaf586-B33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12879-015-0964-2","article-title":"Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study","volume":"15","author":"Theron","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2026052019231178800_ciaf586-B34","doi-asserted-by":"crossref","first-page":"26108","DOI":"10.1038\/s41598-024-74318-3","article-title":"The impact of physiological state and environmental stress on bacterial load estimation methodologies for Mycobacterium tuberculosis","volume":"14","author":"Maitra","year":"2024","journal-title":"Sci Rep"},{"key":"2026052019231178800_ciaf586-B35","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/jac\/dkx317","article-title":"Modelling of mycobacterial load reveals bedaquiline's exposure\u2013response relationship in patients with drug-resistant TB","volume":"72","author":"Svensson","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf586\/64922872\/ciaf586.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/5\/e1014\/64922872\/ciaf586.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/5\/e1014\/64922872\/ciaf586.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:23:20Z","timestamp":1779319400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/5\/e1014\/8300779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,24]]},"published-print":{"date-parts":[[2026,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf586","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,15]]},"published":{"date-parts":[[2025,10,24]]}}}